de Leon J - Search Results

1

Clinical Pharmacogenetics Implementation Consortium Guideline for Cytochrome P450 (CYP)2D6 Genotype and Atomoxetine Therapy.

Brown JT, Bishop JR, Sangkuhl K, Nurmi EL, Mueller DJ, Dinh JC, Gaedigk A, Klein TE, Caudle KE, McCracken JT, de Leon J, Leeder JS. Brown JT, et al. Among authors: de leon j. Clin Pharmacol Ther. 2019 Jul;106(1):94-102. doi: 10.1002/cpt.1409. Epub 2019 Apr 13. Clin Pharmacol Ther. 2019. PMID: 30801677 Free PMC article.

2

Pilot study of the cytochrome P450-2D6 genotype in a psychiatric state hospital.

de Leon J, Barnhill J, Rogers T, Boyle J, Chou WH, Wedlund PJ. de Leon J, et al. Am J Psychiatry. 1998 Sep;155(9):1278-80. doi: 10.1176/ajp.155.9.1278. Am J Psychiatry. 1998. PMID: 9734555

3

A pilot study on risperidone metabolism: the role of cytochromes P450 2D6 and 3A.

Bork JA, Rogers T, Wedlund PJ, de Leon J. Bork JA, et al. Among authors: de leon j. J Clin Psychiatry. 1999 Jul;60(7):469-76. J Clin Psychiatry. 1999. PMID: 10453802

4

Extension of a pilot study: impact from the cytochrome P450 2D6 polymorphism on outcome and costs associated with severe mental illness.

Chou WH, Yan FX, de Leon J, Barnhill J, Rogers T, Cronin M, Pho M, Xiao V, Ryder TB, Liu WW, Teiling C, Wedlund PJ. Chou WH, et al. Among authors: de leon j. J Clin Psychopharmacol. 2000 Apr;20(2):246-51. doi: 10.1097/00004714-200004000-00019. J Clin Psychopharmacol. 2000. PMID: 10770465

5

Cytochrome P450 2D6 and antidepressant toxicity and response: what is the evidence?

Wedlund PJ, de Leon J. Wedlund PJ, et al. Among authors: de leon j. Clin Pharmacol Ther. 2004 May;75(5):373-5. doi: 10.1016/j.clpt.2004.01.002. Clin Pharmacol Ther. 2004. PMID: 15116048 No abstract available.

6

The CYP2D6 poor metabolizer phenotype may be associated with risperidone adverse drug reactions and discontinuation.

de Leon J, Susce MT, Pan RM, Fairchild M, Koch WH, Wedlund PJ. de Leon J, et al. J Clin Psychiatry. 2005 Jan;66(1):15-27. doi: 10.4088/jcp.v66n0103. J Clin Psychiatry. 2005. PMID: 15669884

7

A poor metabolizer for cytochromes P450 2D6 and 2C19: a case report on antidepressant treatment.

Johnson M, Markham-Abedi C, Susce MT, Murray-Carmichael E, McCollum S, de Leon J. Johnson M, et al. Among authors: de leon j. CNS Spectr. 2006 Oct;11(10):757-60. doi: 10.1017/s1092852900014887. CNS Spectr. 2006. PMID: 17008819

8

Pharmacogenomics in psychiatry: from therapeutic drug monitoring to genomic medicine.

Crettol S, de Leon J, Hiemke C, Eap CB. Crettol S, et al. Among authors: de leon j. Clin Pharmacol Ther. 2014 Mar;95(3):254-7. doi: 10.1038/clpt.2013.221. Epub 2013 Nov 6. Clin Pharmacol Ther. 2014. PMID: 24196844 Review. No abstract available.

9

Translating Pharmacogenetics to Clinical Practice: Do Cytochrome P450 2D6 Ultrarapid Metabolizers Need Higher Atomoxetine Doses?

de Leon J. de Leon J. J Am Acad Child Adolesc Psychiatry. 2015 Jul;54(7):532-4. doi: 10.1016/j.jaac.2015.04.003. J Am Acad Child Adolesc Psychiatry. 2015. PMID: 26088654 Review. No abstract available.

10

CYP2D6 Genetic Polymorphisms and Risperidone Pharmacokinetics: A Systematic Review and Meta-analysis.

Zhang L, Brown SJ, Shan Y, Lee AM, Allen JD, Eum S, de Leon J, Bishop JR. Zhang L, et al. Among authors: de leon j. Pharmacotherapy. 2020 Jul;40(7):632-647. doi: 10.1002/phar.2434. Epub 2020 Jul 12. Pharmacotherapy. 2020. PMID: 32519344

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

829 results

Search Page

Filters